SCHEMBL10053141

SCHEMBL10053141

CC(=O)OCc1cccc(C(C)C)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
MRGPRX4 Q96LA9 1/20 0.47
CYP3A4 P08684 2/20 0.46
BCHE P06276 1/20 0.43
IDH1 O75874 1/20 0.43
HDAC4 P56524 2/20 0.42
HDAC8 Q9BY41 2/20 0.42
KDM4E B2RXH2 2/20 0.42
CA2 P00918 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MDM4 O15151 1/20 0.42
CA1 P00915 1/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
TYR P14679 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
CA5A P35218 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27433747 0.84 MRGPRX4 (0.45) ALDH1A1MRGPRX4CYP3A4BCHEHDAC4
SCHEMBL21465877 0.84 ALDH1A1 (0.54) ALDH1A1CYP3A4IDH1CA2SMN1; SMN2
SCHEMBL6709375 0.84 ALDH1A1 (0.73) ALDH1A1CYP3A4IDH1KDM4ECA2
SCHEMBL13498025 0.83 MRGPRX4 (0.44) ALDH1A1MRGPRX4CYP3A4BCHEHDAC4
SCHEMBL18025553 0.81 TNKS2 (0.45) ALDH1A1CYP3A4BCHEHDAC4HDAC8
SCHEMBL19245035 0.80 MRGPRX4 (0.42) ALDH1A1MRGPRX4KDM4EMAPTPTGER3
SCHEMBL8006943 0.80 AOC3 (0.50) ALDH1A1MRGPRX4CYP3A4HDAC4HDAC8
Hydrochloric Acid SCHEMBL7995210 0.79 AOC3 (0.51) ALDH1A1MRGPRX4SMN1; SMN2HPGDPTGER3
SCHEMBL873057 0.79 ALDH1A1 (0.60) ALDH1A1CYP3A4KDM4ESMN1; SMN2RXRA
SCHEMBL2385123 0.79 ALDH1A1 (0.66) ALDH1A1CYP3A4IDH1TYRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106031-B2 Hydrolytically-resistant boron-containing therapeutics and methods of use ANACOR PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-8106031-B2 Hydrolytically-resistant boron-containing therapeutics and methods of use ANACOR PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
EP-1947102-A1 Compositions comprising diazepinoindole derivatives as kinase inhibitors Pfizer, Inc. (US) 2008-07-23 EP disclosed
US-20070265226-A1 Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use ANACOR PHARMACEUTICALS (US) 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265226-A1 Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use GAA, BTD, MANBA ALDH1A1 2088/4885MRGPRX4 1987/4885CYP3A4 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.